{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:11Z","timestamp":1787020151087,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Gansu Provincial People's Hospital In-Hospital Fund","award":["No.23GSSYA-17"],"award-info":[{"award-number":["No.23GSSYA-17"]}]},{"name":"he Natural Science Foundation of Gansu Province","award":["No.26JRRA760"],"award-info":[{"award-number":["No.26JRRA760"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04930-2","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T10:14:02Z","timestamp":1779185642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Circular RNAs in hepatocellular carcinoma: a systematic qualitative review of regulatory mechanisms, therapeutic resistance, and clinical translation"],"prefix":"10.1186","volume":"26","author":[{"given":"Beining","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninggang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoliang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"3","key":"4930_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4930_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3892\/ijo.2020.5035","volume":"57","author":"YX Gao","year":"2020","unstructured":"Gao YX, Yang TW, Yin JM, et al. Progress and prospects of biomarkers in primary liver cancer (Review). Int J Oncol. 2020;57(1):54\u201366. https:\/\/doi.org\/10.3892\/ijo.2020.5035.","journal-title":"Int J Oncol"},{"issue":"3","key":"4930_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3892\/ijmm.2026.5729","volume":"57","author":"XM Chen","year":"2026","unstructured":"Chen XM, Liang YB, Zuo JX, Yang ZS, Zhang LY, Zhang XY, et al. ZG16B: A key regulator of tumor progression and immune microenvironment modulation in cancer (Review). Int J Mol Med. 2026;57(3):58. https:\/\/doi.org\/10.3892\/ijmm.2026.5729.","journal-title":"Int J Mol Med"},{"key":"4930_CR4","doi-asserted-by":"publisher","first-page":"e18761429310703","DOI":"10.2174\/0118761429310703240823045808","volume":"17","author":"B Sensi","year":"2024","unstructured":"Sensi B, Angelico R, Toti L, Conte LE, Coppola A, Tisone G, Manzia TM. Mechanism, Potential, and Concerns of Immunotherapy for Hepatocellular Carcinoma and Liver Transplantation. Curr Mol Pharmacol. 2024;17:e18761429310703. https:\/\/doi.org\/10.2174\/0118761429310703240823045808.","journal-title":"Curr Mol Pharmacol"},{"key":"4930_CR5","doi-asserted-by":"publisher","DOI":"10.1159\/000549355","author":"J Li","year":"2025","unstructured":"Li J, Liang YB, Wang QB, Luo WL, Chen XM, Lakang Y, et al. Rechallenge with Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma: A Narrative Review. Liver Cancer. 2025. https:\/\/doi.org\/10.1159\/000549355.","journal-title":"Liver Cancer"},{"key":"4930_CR6","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.2147\/JHC.S556306","volume":"12","author":"WL Luo","year":"2025","unstructured":"Luo WL, Wang QB, Li YK, Liang YB, Li J, Chen XM, et al. Impact of Middle Hepatic Vein Resection During Hemihepatectomy on Surgical Outcomes and Long-Term Prognosis in Hepatocellular Carcinoma: A Retrospective Study. J Hepatocell Carcinoma. 2025;12:2681\u201392. https:\/\/doi.org\/10.2147\/JHC.S556306.","journal-title":"J Hepatocell Carcinoma"},{"key":"4930_CR7","doi-asserted-by":"publisher","first-page":"e18761429358008","DOI":"10.2174\/0118761429358008250305070518","volume":"17","author":"W Xu","year":"2024","unstructured":"Xu W, Liao S, Hu Y, Huang Y, Zhou J. Upregulation of miR-3130-5p Enhances Hepatocellular Carcinoma Growth by Suppressing Ferredoxin 1. Curr Mol Pharmacol. 2024;17:e18761429358008. https:\/\/doi.org\/10.2174\/0118761429358008250305070518.","journal-title":"Curr Mol Pharmacol"},{"issue":"3","key":"4930_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2174\/0113892029313473240919105819","volume":"26","author":"X He","year":"2025","unstructured":"He X, Ma J, Yan X, Yang X, Wang P, Zhang L, Li N, Shi Z. CDT1 is a Potential Therapeutic Target for the Progression of NAFLD to HCC and the Exacerbation of Cancer. Curr Genomics. 2025;26(3):225\u201343. https:\/\/doi.org\/10.2174\/0113892029313473240919105819.","journal-title":"Curr Genomics"},{"issue":"1","key":"4930_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2174\/0113892029308243240709073945","volume":"26","author":"IP Gudivada","year":"2025","unstructured":"Gudivada IP, Amajala KC. Integrative Bioinformatics Analysis for Targeting Hub Genes in Hepatocellular Carcinoma Treatment. Curr Genomics. 2025;26(1):48\u201380. https:\/\/doi.org\/10.2174\/0113892029308243240709073945.","journal-title":"Curr Genomics"},{"issue":"12","key":"4930_CR10","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.3390\/cells11121948","volume":"11","author":"H Meng","year":"2022","unstructured":"Meng H, Niu R, Huang C, Li J. Circular RNA as a Novel Biomarker and Therapeutic Target for HCC. Cells. 2022;11(12):1948. https:\/\/doi.org\/10.3390\/cells11121948.","journal-title":"Cells"},{"issue":"1","key":"4930_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-024-02056-1","volume":"23","author":"Y Ji","year":"2024","unstructured":"Ji Y, Ni C, Shen Y, et al. ESRP1-mediated biogenesis of circPTPN12 inhibits hepatocellular carcinoma progression by PDLIM2\/ NF-\u03baB pathway. Mol Cancer. 2024;23(1):143. https:\/\/doi.org\/10.1186\/s12943-024-02056-1.","journal-title":"Mol Cancer"},{"issue":"16","key":"4930_CR12","doi-asserted-by":"publisher","first-page":"e2306915","DOI":"10.1002\/advs.202306915","volume":"11","author":"X Hu","year":"2024","unstructured":"Hu X, Chen G, Huang Y, et al. Integrated Multiomics Reveals Silencing of has_circ_0006646 Promotes TRIM21-Mediated NCL Ubiquitination to Inhibit Hepatocellular Carcinoma Metastasis. Adv Sci (Weinh). 2024;11(16):e2306915. https:\/\/doi.org\/10.1002\/advs.202306915.","journal-title":"Adv Sci (Weinh)"},{"issue":"12","key":"4930_CR13","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cell.2022.04.021","volume":"185","author":"CX Liu","year":"2022","unstructured":"Liu CX, Chen LL. Circular RNAs: Characterization, cellular roles, and applications. Cell. 2022;185(12):2016\u201334. https:\/\/doi.org\/10.1016\/j.cell.2022.04.021.","journal-title":"Cell"},{"issue":"3","key":"4930_CR14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41571-021-00585-y","volume":"19","author":"LS Kristensen","year":"2022","unstructured":"Kristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 2022;19(3):188\u2013206. https:\/\/doi.org\/10.1038\/s41571-021-00585-y.","journal-title":"Nat Rev Clin Oncol"},{"issue":"38","key":"4930_CR15","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1038\/s41388-023-02780-w","volume":"42","author":"G Pisignano","year":"2023","unstructured":"Pisignano G, Michael DC, Visal TH, et al. Going circular: history, present, and future of circRNAs in cancer. Oncogene. 2023;42(38):2783\u2013800. https:\/\/doi.org\/10.1038\/s41388-023-02780-w.","journal-title":"Oncogene"},{"issue":"12","key":"4930_CR16","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3390\/biom14121503","volume":"14","author":"F Xu","year":"2024","unstructured":"Xu F, Xiao Q, Du WW, et al. CircRNA: Functions, Applications and Prospects. Biomolecules. 2024;14(12):1503. https:\/\/doi.org\/10.3390\/biom14121503.","journal-title":"Biomolecules"},{"key":"4930_CR17","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.2147\/JHC.S459633","volume":"11","author":"Y Feng","year":"2024","unstructured":"Feng Y, Liang L, Jia W, et al. Circ_0007386 Promotes the Progression of Hepatocellular Carcinoma Through the miR-507\/ CCNT2 Axis. J Hepatocell Carcinoma. 2024;11:1095\u2013112. https:\/\/doi.org\/10.2147\/JHC.S459633.","journal-title":"J Hepatocell Carcinoma"},{"issue":"1","key":"4930_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12943-024-02030-x","volume":"23","author":"XY Zhang","year":"2024","unstructured":"Zhang XY, Li SS, Gu YR, et al. CircPIAS1 promotes hepatocellular carcinoma progression by inhibiting ferroptosis via the miR-455-3p\/NUPR1\/FTH1 axis. Mol Cancer. 2024;23(1):113. https:\/\/doi.org\/10.1186\/s12943-024-02030-x.","journal-title":"Mol Cancer"},{"issue":"1","key":"4930_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s40164-022-00342-6","volume":"11","author":"XH Lin","year":"2022","unstructured":"Lin XH, Liu ZY, Zhang DY, et al. circRanGAP1\/miR-27b-3p\/NRAS Axis may promote the progression of hepatocellular Carcinoma. Exp Hematol Oncol. 2022;11(1):92. https:\/\/doi.org\/10.1186\/s40164-022-00342-6.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"4930_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13046-022-02378-2","volume":"41","author":"Y Liu","year":"2022","unstructured":"Liu Y, Song J, Zhang H, et al. EIF4A3-induced circTOLLIP promotes the progression of hepatocellular carcinoma via the miR-516a-5p\/PBX3\/EMT pathway. J Exp Clin Cancer Res. 2022;41(1):164. https:\/\/doi.org\/10.1186\/s13046-022-02378-2.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"4930_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41419-024-06570-4","volume":"15","author":"C Tang","year":"2024","unstructured":"Tang C, Zhuang H, Wang W, et al. CircNUP54 promotes hepatocellular carcinoma progression via facilitating HuR cytoplasmic export and stabilizing BIRC3 mRNA. Cell Death Dis. 2024;15(3):191. https:\/\/doi.org\/10.1038\/s41419-024-06570-4.","journal-title":"Cell Death Dis"},{"key":"4930_CR22","doi-asserted-by":"publisher","first-page":"111243","DOI":"10.1016\/j.cellsig.2024.111243","volume":"120","author":"J Li","year":"2024","unstructured":"Li J, Qian L, Ge M, et al. hsa_circ_0000518 stimulates the malignant progression of hepatocellular carcinoma via regulating ITGA5 to activate the Warburg effect. Cell Signal. 2024;120:111243. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111243.","journal-title":"Cell Signal"},{"key":"4930_CR23","doi-asserted-by":"publisher","first-page":"110065","DOI":"10.1016\/j.cellsig.2021.110065","volume":"86","author":"G Yang","year":"2021","unstructured":"Yang G, Xu Q, Wan Y, et al. Circ-CSPP1 knockdown suppresses hepatocellular carcinoma progression through miR-493-5p releasing-mediated HMGB1 downregulation. Cell Signal. 2021;86:110065. https:\/\/doi.org\/10.1016\/j.cellsig.2021.110065.","journal-title":"Cell Signal"},{"issue":"10","key":"4930_CR24","doi-asserted-by":"publisher","first-page":"107818","DOI":"10.1016\/j.isci.2023.107818","volume":"26","author":"M Lai","year":"2023","unstructured":"Lai M, Liu M, Li D, et al. circELMOD3 increases and stabilizes TRIM13 by sponging miR-6864-5p and direct binding to inhibit HCC progression. iScience. 2023;26(10):107818. https:\/\/doi.org\/10.1016\/j.isci.2023.107818.","journal-title":"iScience"},{"issue":"1","key":"4930_CR25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12943-022-01619-4","volume":"21","author":"L Liu","year":"2022","unstructured":"Liu L, Gu M, Ma J, et al. CircGPR137B\/miR-4739\/FTO feedback loop suppresses tumorigenesis and metastasis of hepatocellular carcinoma. Mol Cancer. 2022;21(1):149. https:\/\/doi.org\/10.1186\/s12943-022-01619-4.","journal-title":"Mol Cancer"},{"key":"4930_CR26","doi-asserted-by":"publisher","first-page":"111298","DOI":"10.1016\/j.cellsig.2024.111298","volume":"122","author":"YN Wang","year":"2024","unstructured":"Wang YN, Cao D, Liu J, et al. CircATF6 inhibits hepatocellular carcinoma progression by suppressing calreticulin-mediated Wnt\/\u03b2-catenin signaling pathway. Cell Signal. 2024;122:111298. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111298.","journal-title":"Cell Signal"},{"issue":"1","key":"4930_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12943-023-01882-z","volume":"22","author":"L Xu","year":"2023","unstructured":"Xu L, Wang P, Li L, et al. circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma. Mol Cancer. 2023;22(1):174. https:\/\/doi.org\/10.1186\/s12943-023-01882-z.","journal-title":"Mol Cancer"},{"issue":"8","key":"4930_CR28","doi-asserted-by":"publisher","first-page":"e2103817","DOI":"10.1002\/advs.202103817","volume":"9","author":"S Chen","year":"2022","unstructured":"Chen S, Cao X, Zhang J, et al. circVAMP3 Drives CAPRIN1 Phase Separation and Inhibits Hepatocellular Carcinoma by Suppressing c-Myc Translation. Adv Sci (Weinh). 2022;9(8):e2103817. https:\/\/doi.org\/10.1002\/advs.202103817.","journal-title":"Adv Sci (Weinh)"},{"issue":"11","key":"4930_CR29","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1038\/s12276-023-01108-8","volume":"55","author":"J Yu","year":"2023","unstructured":"Yu J, Li W, Hou GJ, et al. Circular RNA cFAM210A, degradable by HBx, inhibits HCC tumorigenesis by suppressing YBX1 transactivation. Exp Mol Med. 2023;55(11):2390\u2013401. https:\/\/doi.org\/10.1038\/s12276-023-01108-8.","journal-title":"Exp Mol Med"},{"issue":"14","key":"4930_CR30","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.7150\/ijbs.86227","volume":"19","author":"Y Ruan","year":"2023","unstructured":"Ruan Y, Chen T, Zheng L, et al. cDCBLD2 mediates sorafenib resistance in hepatocellular carcinoma by sponging miR-345-5p binding to the TOP2A coding sequence. Int J Biol Sci. 2023;19(14):4608\u201326. https:\/\/doi.org\/10.7150\/ijbs.86227.","journal-title":"Int J Biol Sci"},{"key":"4930_CR31","doi-asserted-by":"publisher","first-page":"154435","DOI":"10.1016\/j.prp.2023.154435","volume":"245","author":"C Xu","year":"2023","unstructured":"Xu C, Sun W, Liu J, et al. Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338-3p\/RAB1B axis. Pathol Res Pract. 2023;245:154435. https:\/\/doi.org\/10.1016\/j.prp.2023.154435.","journal-title":"Pathol Res Pract"},{"issue":"10","key":"4930_CR32","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.gastrohep.2021.11.007","volume":"45","author":"Q Yang","year":"2022","unstructured":"Yang Q, Wu G. CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expression. Gastroenterol Hepatol. 2022;45(10):742\u201352. https:\/\/doi.org\/10.1016\/j.gastrohep.2021.11.007.","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"4930_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12943-024-02224-3","volume":"24","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yao R, Li M, et al. CircTTC13 promotes sorafenib resistance in hepatocellular carcinoma through the inhibition of ferroptosis by targeting the miR-513a-5p\/SLC7A11 axis. Mol Cancer. 2025;24(1):32. https:\/\/doi.org\/10.1186\/s12943-024-02224-3.","journal-title":"Mol Cancer"},{"issue":"6","key":"4930_CR34","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1007\/s10620-024-08401-0","volume":"69","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wang W, Mo S, Sun X. DEAD-Box Helicase 17 circRNA (circDDX17) Reduces Sorafenib Resistance and Tumorigenesis in Hepatocellular Carcinoma. Dig Dis Sci. 2024;69(6):2096\u2013108. https:\/\/doi.org\/10.1007\/s10620-024-08401-0.","journal-title":"Dig Dis Sci"},{"key":"4930_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ncrna.2025.05.007","volume":"14","author":"M Cao","year":"2025","unstructured":"Cao M, Li Y, Su X, et al. Exosome-derived hsa_circ_0007132 promotes lenvatinib resistance by inhibiting the ubiquitin-mediated degradation of NONO. Noncoding RNA Res. 2025;14:1\u201313. https:\/\/doi.org\/10.1016\/j.ncrna.2025.05.007.","journal-title":"Noncoding RNA Res"},{"issue":"20","key":"4930_CR36","doi-asserted-by":"publisher","first-page":"e2410591","DOI":"10.1002\/advs.202410591","volume":"12","author":"Y Tang","year":"2025","unstructured":"Tang Y, Yuan F, Cao M, et al. CircRNA-mTOR Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance Through the PSIP1\/c-Myc Axis. Adv Sci (Weinh). 2025;12(20):e2410591. https:\/\/doi.org\/10.1002\/advs.202410591.","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"4930_CR37","doi-asserted-by":"publisher","first-page":"110999","DOI":"10.1016\/j.ygeno.2025.110999","volume":"117","author":"F Yuan","year":"2025","unstructured":"Yuan F, Tang Y, Liang H, et al. CircPIK3C3 inhibits hepatocellular carcinoma progression and lenvatinib resistance by suppressing the Wnt\/\u03b2-catenin pathway via the miR-452-5p\/SOX15 axis. Genomics. 2025;117(2):110999. https:\/\/doi.org\/10.1016\/j.ygeno.2025.110999.","journal-title":"Genomics"},{"key":"4930_CR38","doi-asserted-by":"publisher","first-page":"217470","DOI":"10.1016\/j.canlet.2025.217470","volume":"612","author":"L Yang","year":"2025","unstructured":"Yang L, Tan W, Wang M, et al. circCCNY enhances lenvatinib sensitivity and suppresses immune evasion in hepatocellular carcinoma by serving as a scaffold for SMURF1 mediated HSP60 degradation. Cancer Lett. 2025;612:217470. https:\/\/doi.org\/10.1016\/j.canlet.2025.217470.","journal-title":"Cancer Lett"},{"issue":"1","key":"4930_CR39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","volume":"12","author":"S Apisarnthanarax","year":"2022","unstructured":"Apisarnthanarax S, Barry A, Cao M, et al. External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2022;12(1):28\u201351. https:\/\/doi.org\/10.1016\/j.prro.2021.09.004.","journal-title":"Pract Radiat Oncol"},{"key":"4930_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2147\/JHC.S364742","volume":"9","author":"X Li","year":"2022","unstructured":"Li X, Yao Q, Liu C, et al. Macrotrabecular-Massive Hepatocellular Carcinoma: What Should We Know? J Hepatocell Carcinoma. 2022;9:379\u201387. https:\/\/doi.org\/10.2147\/JHC.S364742.","journal-title":"J Hepatocell Carcinoma"},{"issue":"2","key":"4930_CR41","doi-asserted-by":"publisher","first-page":"100678","DOI":"10.1016\/j.aohep.2022.100678","volume":"27","author":"S Zhu","year":"2022","unstructured":"Zhu S, Chen Y, Ye H, et al. Circ-LARP1B knockdown restrains the tumorigenicity and enhances radiosensitivity by regulating miR-578\/IGF1R axis in hepatocellular carcinoma. Ann Hepatol. 2022;27(2):100678. https:\/\/doi.org\/10.1016\/j.aohep.2022.100678.","journal-title":"Ann Hepatol"},{"issue":"6","key":"4930_CR42","doi-asserted-by":"publisher","first-page":"101536","DOI":"10.1016\/j.aohep.2024.101536","volume":"29","author":"K Yang","year":"2024","unstructured":"Yang K, Ding Y, Han J, He R. CircROBO1 knockdown improves the radiosensitivity of hepatocellular carcinoma by regulating RAD21. Ann Hepatol. 2024;29(6):101536. https:\/\/doi.org\/10.1016\/j.aohep.2024.101536.","journal-title":"Ann Hepatol"},{"issue":"1","key":"4930_CR43","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12935-023-03168-2","volume":"23","author":"P Hu","year":"2023","unstructured":"Hu P, Lin L, Huang T, et al. Circular RNA circEYA3 promotes the radiation resistance of hepatocellular carcinoma via the IGF2BP2\/DTX3L axis. Cancer Cell Int. 2023;23(1):308. https:\/\/doi.org\/10.1186\/s12935-023-03168-2.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"4930_CR44","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1159\/000527696","volume":"41","author":"X Wang","year":"2023","unstructured":"Wang X, Zhang J, Luo F, Shen Y. Application of Circular RNA Circ_0071662 in the Diagnosis and Prognosis of Hepatocellular Carcinoma and Its Response to Radiotherapy. Dig Dis. 2023;41(3):431\u20138. https:\/\/doi.org\/10.1159\/000527696.","journal-title":"Dig Dis"},{"issue":"Pt 2","key":"4930_CR45","doi-asserted-by":"publisher","first-page":"130541","DOI":"10.1016\/j.ijbiomac.2024.130541","volume":"264","author":"L Lin","year":"2024","unstructured":"Lin L, Hu P, Luo M, et al. CircNOP14 increases the radiosensitivity of hepatocellular carcinoma via inhibition of Ku70-dependent DNA damage repair. Int J Biol Macromol. 2024;264(Pt 2):130541. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.130541.","journal-title":"Int J Biol Macromol"},{"key":"4930_CR46","doi-asserted-by":"publisher","first-page":"1714314","DOI":"10.3389\/fimmu.2026.1714314","volume":"17","author":"J Li","year":"2026","unstructured":"Li J, Liang YB, Chen XM, Ou ZY, Wang QB, Luo WL, et al. Prognostic value of lymphatic vessel density in the capsule of early-stage hepatocellular carcinoma: implications for postoperative recurrence risk. Front Immunol. 2026;17:1714314. https:\/\/doi.org\/10.3389\/fimmu.2026.1714314.","journal-title":"Front Immunol"},{"key":"4930_CR47","doi-asserted-by":"publisher","first-page":"1466424","DOI":"10.3389\/fphar.2024.1466424","volume":"15","author":"H Zhang","year":"2024","unstructured":"Zhang H, Pei S, Li J, et al. Insights about exosomal circular RNAs as novel biomarkers and therapeutic targets for hepatocellular carcinoma. Front Pharmacol. 2024;15:1466424. https:\/\/doi.org\/10.3389\/fphar.2024.1466424.","journal-title":"Front Pharmacol"},{"key":"4930_CR48","doi-asserted-by":"publisher","first-page":"1483521","DOI":"10.3389\/fonc.2024.1483521","volume":"14","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Qi S, Zhang R, et al. Diagnosis of hepatocellular carcinoma using liquid biopsy-based biomarkers: a systematic review and network meta-analysis. Front Oncol. 2024;14:1483521. https:\/\/doi.org\/10.3389\/fonc.2024.1483521.","journal-title":"Front Oncol"},{"issue":"6","key":"4930_CR49","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922\u201365. https:\/\/doi.org\/10.1097\/HEP.0000000000000466.","journal-title":"Hepatology"},{"issue":"6","key":"4930_CR50","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421\u201346. https:\/\/doi.org\/10.1038\/s41573-019-0017-4.","journal-title":"Nat Rev Drug Discov"},{"key":"4930_CR51","doi-asserted-by":"publisher","first-page":"1720361","DOI":"10.3389\/fphar.2025.1720361","volume":"16","author":"JM Cronin","year":"2025","unstructured":"Cronin JM, Yu AM. Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions. Front Pharmacol. 2025;16:1720361. https:\/\/doi.org\/10.3389\/fphar.2025.1720361.","journal-title":"Front Pharmacol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04930-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04930-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04930-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:02:23Z","timestamp":1783699343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04930-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4930"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04930-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This systematic review did not involve new studies of human participants, human data, human tissue, or animals performed by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"437"}}